Latest Information Update: 16 Jul 2002
At a glance
- Originator CV Therapeutics
- Mechanism of Action Partial fatty acid oxidation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Angina pectoris
Most Recent Events
- 13 Sep 2000 New profile
- 13 Sep 2000 Preclinical development for Angina pectoris in USA (Unknown route)